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Introduction {#sec1}
============

Genes that function in epigenetic regulation (epigenes), including those involved in chromatin remodeling and histone modifications, are increasingly being identified in the etiology of a variety of neurodevelopmental disorders. Two such disorders include CHARGE syndrome \[MIM: [214800](214800){#intref0010}\], caused by heterozygous mutations in chromodomain helicase DNA-binding protein 7 (*CHD7* \[MIM: [608892](608892){#intref0015}\]), and Kabuki syndrome \[MIM: [147920](147920){#intref0020}\] caused by heterozygous mutations in lysine (K)-specific methyltransferase 2D (*KMT2D* \[MIM: [602113](602113){#intref0025}\]).[@bib1], [@bib2] CHARGE syndrome is characterized by Coloboma, Heart defects, Atresia of the choanae, Retardation of growth and development, Genital hypoplasia, and Ear abnormalities including deafness and vestibular disorders. Kabuki syndrome is characterized by a typical facial gestalt, postnatal growth deficiency, congenital heart defects, hearing loss and intellectual disability as well as skeletal, dermatoglyphic, genitourinary, and ophthalmologic anomalies (including coloboma). There is extensive clinical overlap between these two syndromes and clinical distinction can be particularly challenging in early life as the characteristic facial features of Kabuki syndrome often become apparent with age.[@bib3], [@bib4] A molecular link between CHD7 and KMT2D function has been proposed via their known interaction with members of the WAR complex (WDR5 \[WD-repeat protein 5\], ASH2L \[absent, small, homeotic discs-2-like\], and also RBBP5 \[retinoblastoma-binding protein-5\]), which has been shown to be involved in histone methylation.[@bib5], [@bib6] It has been suggested that CHD7 and KMT2D might regulate a common subset of genes via their interaction with the WAR complex, which might explain the overlapping features in CHARGE and Kabuki syndromes.[@bib7]

We and others have previously demonstrated that loss of function (LOF) mutations in epigenes can be associated with specific patterns of DNA methylation (DNAm) alterations that constitute unique signatures.[@bib8], [@bib9], [@bib10] Specifically, unique DNAm signatures are observed in individuals harboring mutations in lysine-specific demethylase 5C (*KDM5C* \[MIM: [314690](314690){#intref0030}\]), which encodes an H3K4 demethylase and causes non-syndromic intellectual disability \[MIM: [300534](300534){#intref0035}\], DNA methyltransferase 1 (*DNMT1* \[MIM: [126375](126375){#intref0040}\]), which cause adult-onset autosomal dominant cerebellar ataxia with deafness and narcolepsy (ADCA-DN \[MIM: [604121](604121){#intref0045}\]), and nuclear receptor binding SET domain protein 1(*NSD1* \[MIM: [606681](606681){#intref0050}\]) which encodes a histone methyltransferase and cause Sotos syndrome \[MIM:[117550](117550){#intref0055}\].[@bib8], [@bib9], [@bib10] Moreover, for *NSD1* we have shown that genes encoding proteins in growth and neurodevelopmental pathways are highly represented in the DNAm signature reflecting the pathophysiology of the disorder.[@bib8] We hypothesized that comparison of genome-wide DNAm alterations in individuals with heterozygous LOF mutations in *CHD7* and *KMT2D*, respectively, would identify two disease-specific DNAm signatures that would include common target genes and biological pathways, reflecting the clinical overlap of these two conditions, as well as distinct target genes reflecting divergent clinical features.

Here we analyze DNAm using whole blood from individuals with a clinical diagnosis of either CHARGE or Kabuki syndrome with LOF mutations in *CHD7* (*CHD7*^LOF^) or *KMT2D* (*KMT2D*^LOF^), respectively. When compared to controls, *CHD7*^LOF^ and *KMT2D*^LOF^ demonstrate specific sets of differentially methylated CpGs, which we defined as two unique DNAm signatures. We show that the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signatures both demonstrate high sensitivity and specificity, not only differentiating individuals with LOF mutations from controls but also differentiating individuals with *CHD7*^LOF^ and *KMT2D*^LOF^ from each other. As such, these DNAm signatures can offer a molecular means of distinguishing between CHARGE and Kabuki syndromes when clinical distinction is challenging. We also demonstrate that the specific DNAm signatures can be used to differentiate pathogenic mutations in *CHD7* and *KMT2D* from benign sequence variants. Finally, analysis of the DNAm gene targets identified in the *CHD7*^LOF^ and *KMT2D*^LOF^-specific DNAm signatures show gain of DNAm at homeobox A5 (*HOXA5* \[MIM: [142592](142592){#intref0060}\]) in both signatures, which may account for some of the clinical overlap observed in CHARGE and Kabuki syndromes. There are also distinct DNAm alterations in each of the signatures that likely drive molecular pathways contributing to the distinct clinical features in these two syndromes.

Material and Methods {#sec2}
====================

Research Participants {#sec2.1}
---------------------

### Discovery Cohort {#sec2.1.1}

Individuals with a clinical diagnosis of CHARGE syndrome and *CHD7* LOF mutations (nonsense, frameshift mutations resulting in a premature stop, exonic deletions, and splice site mutations) were recruited through the Division of Clinical and Metabolic Genetics at the Hospital for Sick Children in Toronto, Ontario, Service de Génétique, Centre de Référence Anomalies du Développement de l'Ouest, CHU Poitiers, France and Our Lady's Hospital for Sick Children in Dublin, Ireland (n = 19). Individuals with a clinical diagnosis of Kabuki syndrome and *KMT2D* LOF mutations (nonsense and frameshift mutations resulting in a premature stop) were recruited at the Hospital for Sick Children and the Center for Human Genetics, Inc. (n = 11). A detailed list of the specific *CHD7* (GenBank: [NM_017780.3](ncbi-n:NM_017780.3){#intref0065}) and *KMT2D* (GenBank: [NM_003482.3](ncbi-n:NM_003482.3){#intref0070}) LOF mutations, designated *CHD7*^LOF^ and *KMT2D*^LOF^ can be found in [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}. Phenotypic information on individuals with *CHD7*^LOF^ and *KMT2D*^LOF^ is provided in [Tables S3](#mmc2){ref-type="supplementary-material"} and [S4](#mmc2){ref-type="supplementary-material"}. The majority of the individuals in our Discovery and control cohorts are of European descent: *CHD7*^LOF^ (16/19); *CHD7*^LOF^ cohort controls (28/29); *KMT2D*^LOF^ (10/11); *KMT2D*^LOF^ cohort controls (9/11). These cohorts were used for the derivation of the DNAm signatures. Informed consent was obtained from all research participants according to the protocol approved by the Research Ethics Board of the Hospital for Sick Children (REB\#0019980189).

### Validation Cohort {#sec2.1.2}

Anonymized DNA samples from individuals with *CHD7* or *KMT2D* sequence variants (n = 56) including pathogenic, likely pathogenic, and variants of uncertain significance (VUS) were obtained from PreventionGenetics, USA ([Table S5](#mmc1){ref-type="supplementary-material"}). There was also one sample from an individual with a pathogenic mutation in lysine demethylase 6A (*KDM6A* c.2668_2669dupTA (p.Pro891Thrfs^∗^8); GenBank: [NM_021140.2](ncbi-n:NM_021140.2){#intref0075}; \[MIM: [300128](300128){#intref0080}\]; Kabuki syndrome 2 \[MIM: [300867](300867){#intref0085}\]) in the anonymized cohort. All variants which differed from the reference sequences were interpreted using American College of Medical Genetics and Genomics (ACMG) Guidelines[@bib11] with slight modifications, which include previously unpublished de novo LOF variants being reported as likely pathogenic, instead of pathogenic as is in the ACMG guidelines.

### Cohort with CHD7 and KMT2D Sequence Variants, Excluding LOF {#sec2.1.3}

Individuals with *CHD7* (n = 13) or *KMT2D* (n = 10) VUS including missense and splice site variants were recruited from the same institutions as the *CHD7* and *KMT2D* Discovery Cohorts (see above). Independent in silico prediction algorithms, namely PolyPhen-2,[@bib12] SIFT,[@bib13] Mutation Taster,[@bib14] and ESE finder[@bib15], [@bib16] were used to evaluate the pathogenicity of the mutations in each case ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Phenotypic information available for the individuals is provided in [Tables S3](#mmc2){ref-type="supplementary-material"} and [S4](#mmc2){ref-type="supplementary-material"}. Individuals with *CHD7* sequence variants underwent clinical classification utilizing the criteria established by Verloes[@bib17] and Hale[@bib18] ([Table 1](#tbl1){ref-type="table"}).

### Control DNA Samples {#sec2.1.4}

Age- and sex- matched controls for our discovery and validation cohorts were obtained from three sources ([Table S6](#mmc2){ref-type="supplementary-material"}). These included the Simons Simplex Collection (SSC; Simons Foundation Autism Research Initiative). [@bib19] The Hospital for Sick Children, and The University of Michigan (Dr. Gregory Hanna).[@bib20] The controls were screened using various neurodevelopmental assessments.[@bib19], [@bib20]

### DNAm Data from Public Databases {#sec2.1.5}

Publically available Illumina HumanMethylation450 microarray data for an additional 162 blood controls, which were not expected to contain pathogenic mutations in either *CHD7* or *KMT2D*, were downloaded from the Gene Expression Omnibus (GEO) data repository, chosen from individuals younger than 50 years of age in five GEO series (GEO: [GSE32148](ncbi-geo:GSE32148){#intref0090}, GEO: [GSE40279](ncbi-geo:GSE40279){#intref0095}, GEO: [GSE41169](ncbi-geo:GSE41169){#intref0100}, GEO: [GSE46648](ncbi-geo:GSE46648){#intref0105}, GEO: [GSE53128](ncbi-geo:GSE53128){#intref0110}; see [Table S7](#mmc2){ref-type="supplementary-material"}).

DNAm Data Processing {#sec2.2}
--------------------

DNA samples were converted using sodium bisulfite (EpiTect PLUS Bisulfite Kit, QIAGEN). The sodium bisulfite converted DNA was then hybridized to the Illumina Infinium HumanMethylation450 BeadChip Array to interrogate over 480,000 CpG sites in the human genome. For both the Discovery and Validation cohorts, cases and controls were randomized on the arrays (modified from[@bib21]). Illumina Genome Studio software was used to perform control probe normalization and background subtraction and to extract DNAm values (β values) for each CpG, which represent the percentage of methylated cytosines. These β values ranged between 0 (no methylation) and 1 (full methylation). We excluded probes located on sex chromosomes, autosomal probes that cross-react with sex chromosome probes, non-specific probes, and probes targeting CpG sites within 5bp of a SNP that has a minor allele frequency above 1%.[@bib22], [@bib23] Subsequent analyses were performed on the remaining 363,979 probes.

*CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Signatures {#sec2.3}
--------------------------------------------

Differential DNAm between individuals with LOF mutations and controls at individual CpGs was identified using three criteria. First, we applied regression modeling implemented in the *limma* Bioconductor package to detect statistically significant differences in DNAm (false discovery rate \[FDR\] corrected p value \< 0.01) attributed to either *CHD7*^LOF^ or *KMT2D*^LOF^ versus controls, while accounting for sex and age ([Figure S1](#mmc1){ref-type="supplementary-material"}) as confounding factors in the model design matrix.[@bib24] The *limma* models were applied to DNAm data logit-transformed into M-values.[@bib25] Second, to account for possible effects related to non-normal distribution of DNAm values at individual CpG sites, we used the non-parametric Mann-Whitney U test at each probe to detect statistically significant DNAm differences (FDR corrected p values \< 0.01) between the respective Discovery Cohorts (*CHD7*^LOF^ or *KMT2D*^LOF^) and the control groups. Third, to ensure robust results, statistically significant probes were additionally filtered for effect size. Delta beta (Δβ) was defined for each probe as the difference between average DNAm in each Discovery Cohort and its control group, respectively. We retained only those significant probes for which the DNAm difference (Δβ) between *CHD7*^LOF^ or *KMT2D*^LOF^ and their controls was greater than 0.10 (10% DNAm difference).

The choice of the significance level p \< 0.01 and the 10% effect size threshold for both *CHD7*^LOF^ and *KMT2D*^LOF^ was guided by the volcano plots of the *limma* regression and the Mann-Whitney U test ([Figure S2](#mmc1){ref-type="supplementary-material"}). The CpG sites that satisfied all three criteria defined the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signatures, respectively ([Tables S8](#mmc2){ref-type="supplementary-material"} and [S9](#mmc2){ref-type="supplementary-material"}).

Building Classification Models with the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Signatures {#sec2.4}
------------------------------------------------------------------------------------

Using the two DNAm signatures, we developed predictive models for scoring individuals with *CHD7* or *KMT2D* sequence variants, based on their DNAm profiles. As the DNAm signatures for *CHD7*^LOF^ and *KMT2D*^LOF^ often appeared in groups corresponding to the same gene or region, the CpG sites were filtered for redundancy in order to be used as predictive data features for the respective models. We applied R *caret* software package to identify highly correlated CpGs and removed redundant data features (using the default threshold of 0.90 correlation in the *findCorrelations* function of *caret*). The remaining CpG sites were used to build the *CHD7*^LOF^ and *KMT2D*^LOF^ classification models.

We then built a support vector machine (SVM) model with linear kernel, using the non-redundant DNAm signatures as data features to predict the putative pathogenicity of each sequence variant. Model training was performed by the R *kernlab* software package via *caret*. The training set comprised the *CHD7*^LOF^ or the *KMT2D*^LOF^ and control samples from the Discovery Cohort. The model was set to return a quantitative predictive score between 0 and 1. The SVM scores were derived in *kernlab* using internally randomized cross-validation and thus exhibit slight variability. Therefore for each individual we determined the average score over 100 scoring trials. We then applied these models to samples from the Validation Cohort, another cohort with *CHD7* or *KMT2D* sequence variants (excluding LOF mutations) and GEO controls. High scores indicate putative pathogenicity of sequence variants in *CHD7* or *KMT2D*, and low scores suggest that the sequence variants are benign.

Assessment of Blood Cell Type Composition Effect {#sec2.5}
------------------------------------------------

To ensure that the *CHD7*^LOF^ and *KMT2D*^LOF^ predictive models were not affected by variation in blood cell type composition, we examined 60 DNAm data samples from Reinius et al., 2012[@bib26] (GEO: [GSE35069](ncbi-geo:GSE35069){#intref0115}). These data represent six healthy control whole-blood samples that were sorted into each of the following cell types: peripheral blood mononuclear cells (PBMC), granulocytes, neutrophils, eosinophils, as well as isolated cell populations (CD4^+^ T cells, CD8^+^ T cells, CD56^+^ NK cells, CD19^+^ B cells, CD14^+^ monocytes). The *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signature classification results were plotted for the cell-type samples from Reinius et al., 2012,[@bib26] together with the *CHD7*^LOF^ or *KMT2D*^LOF^ samples and the matching control samples from our Discovery Cohort ([Figure S3](#mmc1){ref-type="supplementary-material"}). Our goal was to verify that none of the blood-cell subtypes were given high scores by either *CHD7*^LOF^ or *KMT2D*^LOF^ predictive models, confirming the lack of a confounding effect between blood-cell type composition and the DNAm signature-based predictions.

Differentially Methylated Regions in the *CHD7* and *KMT2D* Discovery Cohorts {#sec2.6}
-----------------------------------------------------------------------------

To find genomic regions with DNAm differences in *CHD7*^LOF^ or *KMT2D*^LOF^, we used the bump hunting method,[@bib27] which strengthens the detection of regional differences by combining differential-methylation patterns across neighboring CpG sites.[@bib28] The bump hunting design matrix accounted for the potential confounding effects of the sex and age factors. The analysis initially considered CpGs with Δβ \> 5% by magnitude between cases and controls as candidates for the differentially methylation regions (DMRs), with gaps no more than 500 bp between neighboring CpGs. Statistical significance was established using 1,000 randomized bootstrap iterations, as is recommended in the Bioconductor *bumphunter* package documentation when accounting for confounders. The resulting DMRs were post-filtered to retain only those with p value \< 0.01 and average methylation difference Δβ \> 10% by magnitude across the DMR. To further improve robustness, we also required these DMRs to comprise at least three neighboring CpGs, of which at least one has been already been included in the DNAm signature set for either *CHD7*^LOF^ or *KMT2D*^LOF^, as described above ([Tables S10](#mmc2){ref-type="supplementary-material"} and [S11](#mmc2){ref-type="supplementary-material"}). DMRs are presented using visualization methods adapted from DMRcate software ([Figure S4](#mmc1){ref-type="supplementary-material"}).[@bib29]

Functional Enrichment Analysis {#sec2.7}
------------------------------

To identify prominent functional enrichment patterns, we analyzed the list of differentially methylated CpGs in the context of wider genomic regions using GREAT.[@bib30] We retained only the Gene Ontology (GO) Biological Process[@bib31] functional categories for which at least three genes (including their genomic neighborhoods) were targeted by the *CHD7*^LOF^ or *KMT2D*^LOF^ specific DNAm signatures ([Tables S12](#mmc2){ref-type="supplementary-material"} and [S13](#mmc2){ref-type="supplementary-material"}). The background set of probes to which the comparison was made was defined as the 363,979 autosomal CpGs used as the initial input to our analysis pipeline. All p values were FDR corrected.

DNAm Validation by Sodium Bisulfite Pyrosequencing {#sec2.8}
--------------------------------------------------

Differential DNAm between the *CHD7*^LOF^ and *KMT2D*^LOF^ individuals in the Discovery Cohorts and matching controls was validated for selected genomic loci using pyrosequencing assays. These assays were designed using QIAGEN Assay Design Software v1.0.6 to target-specific CpGs identified by the microarray experiment, as well as adjacent sites ([Table S14](#mmc1){ref-type="supplementary-material"}). DNAm was assessed for the following CpG sites: cg01370449, cg04863892 and cg19759481 *HOXA5*, cg16787483; cg24626752 and cg09823859 (*SLITRK5*; SLIT and NTRK like family member 5 \[MIM: [609680](609680){#intref0120}\]); cg18546840 and cg18871253 (*FOXP2*; Forkhead box P2 \[MIM: [605317](605317){#intref0125}\]),) and cg15254671 (*MYO1F*; myosin IF \[MIM: [601480](601480){#intref0130}\]). Pyrosequencing was done using the PyroMark Q24 system and Pyrosequencing Gold Reagents (QIAGEN). Testing for a statistical difference between all groups was performed using a Kruskal-Wallis test (p \< 0.0001).

Results {#sec3}
=======

DNA Methylation Signatures for *CHD7*^LOF^ and *KDM2D*^LOF^ {#sec3.1}
-----------------------------------------------------------

To determine whether LOF mutations in *CHD7* (*CHD7*^LOF^) generate a specific pattern of DNAm alterations, we compared genome-wide DNAm patterns in 19 *CHD7*^LOF^ individuals (*CHD7*^LOF^ Discovery Cohort) and 29 matched controls. Volcano plots of the results of statistical criteria, specifically *limma* regression modeling, and non-parametric Mann-Whitney U tests, were used to determine a significance level p \< 0.01 and an effect size of a 10% Δβ threshold ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). We identified a set of 163 significant differentially methylated CpG sites for the *CHD7*^LOF^ Discovery Cohort, defined as the *CHD7*^LOF^ DNAm signature ([Table S8](#mmc2){ref-type="supplementary-material"}). Unsupervised hierarchical clustering of the DNAm of each of the samples for these 163 CpGs sites clearly distinguished the *CHD7*^LOF^ individuals from controls ([Figure 1](#fig1){ref-type="fig"}A).

Similarly, analysis of genome-wide DNAm patterns for 11 *KMT2D*^LOF^ individuals (*KMT2D*^LOF^ Discovery Cohort) and 11 matched controls identified a set of 221 significant differentially methylated CpGs for *KMT2D*^LOF^, defined as the *KMT2D*^LOF^ DNAm signature ([Table S9](#mmc2){ref-type="supplementary-material"}). Volcano plots of the *limma* regression and the Mann-Whitney U test for the *KMT2D*^LOF^ Discovery Cohort were used to determine the significance level p \< 0.01 and the 10% effect size ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D) to identify this set of CpGs. Unsupervised hierarchical clustering using the *KMT2D*^LOF^ DNAm signature clearly distinguished the *KMT2D*^LOF^ individuals from controls ([Figure 1](#fig1){ref-type="fig"}B).

Predictive Modeling Using DNAm Signatures for *CHD7*^LOF^ and *KMT2D*^LOF^ {#sec3.2}
--------------------------------------------------------------------------

We used the DNAm signatures for the *CHD7* and *KMT2D* Discovery Cohorts to derive the classification signatures, by removing redundant data features. Removing redundancies from the initial collections of CpG sites (see Methods) resulted in a *CHD7*^LOF^ DNAm classification signature comprising 75 CpGs and a *KMT2D*^LOF^ DNAm classification signature comprised of 112 CpGs ([Tables S8](#mmc2){ref-type="supplementary-material"} and [S9](#mmc2){ref-type="supplementary-material"}). Two SVM classification models were then built using the *CHD7* and *KMT2D* Discovery Cohort samples as training sets and the corresponding non-redundant DNAm signatures as data features.

*CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Signatures Are Independent of Blood Cell Type Composition {#sec3.3}
-------------------------------------------------------------------------------------------

Both CHARGE and Kabuki syndromes can be associated with immune dysfunction although the sub-populations of T cells that are potentially altered represent a small fraction of the total lymphocytes.[@bib32], [@bib33] To ensure that the predictive models were not affected by the variation in blood cell types, the two predictive models were applied to DNAm data from normal whole blood, peripheral blood mononuclear cells (PBMC), granulocytes, and isolated cell populations (CD4^+^ T cells, CD8^+^ T cells, CD56^+^ NK cells, CD19^+^ B cells, CD14^+^ monocytes).[@bib26] Prediction results demonstrated that all individual cell types received low predictive scores, placing them near other controls in our data ([Figure S3](#mmc1){ref-type="supplementary-material"}). This suggests that the prediction of either *CHD7*^LOF^ or *KMT2D*^LOF^ status using the respective DNAm signatures is not influenced by a particular blood cell type within a sample. Clinical blood counts and differentials were available for 7 individuals with *CHD7* mutations (3 LOF; 4 sequence variants) and for 2 individuals with *KMT2D* mutations (1 LOF and 1 sequence variant), and all were within the normal range.

Specificity of *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Classification Signatures {#sec3.4}
--------------------------------------------------------------------------

To quantify the specificity of the DNAm classification signatures and to confirm that the two models do not generate overlapping predictions, we applied the *CHD7*^LOF^ predictive model to the *KMT2D*^LOF^ cohort, and conversely the *KMT2D*^LOF^ predictive model to the *CHD7*^LOF^ cohort. None of the *KMT2D*^LOF^ individuals or controls scored as putative *CHD7*^LOF^ using the *CHD7*^LOF^ classification signature, confirming that the *CHD7*^LOF^ predictive model was specific to *CHD7*^LOF^ ([Figure 2](#fig2){ref-type="fig"}). Similarly, none of the *CHD7*^LOF^ individuals or controls scored as *KMT2D*^LOF^, confirming the specificity of the second model ([Figure 2](#fig2){ref-type="fig"}). Next we assessed the specificity of the predictive analysis on the collection of control blood DNAm data extracted from the GEO repository. All 162 GEO samples had low prediction scores for both *CHD7*^LOF^ and *KMT2D*^LOF^, i.e., they were predicted not to have pathogenic mutations in *CHD7* or *KMT2D* by the corresponding models, demonstrating 100% specificity of the DNAm signatures ([Figure 2](#fig2){ref-type="fig"}).

Validation of *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Classification Signatures Using a Blinded Cohort {#sec3.5}
------------------------------------------------------------------------------------------------

Next we applied the predictive models for *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm classification signatures in a blinded fashion to a cohort of individuals with either *CHD7* or *KMT2D* mutations classified as pathogenic, likely pathogenic or variants of unknown significance (VUS; Validation Cohort). After the prediction scores were generated, the mutation classification was unblinded for comparison to the reported variant classification ([Figure 3](#fig3){ref-type="fig"}). The *CHD7*^LOF^ DNAm signature predictive model generated high scores for all of the *CHD7* mutation samples (n = 20) that were classified as pathogenic or likely pathogenic. The same was true of the *KMT2D*^LOF^ model (n = 8). Thus, both predictive models demonstrated the ability to correctly classify pathogenic mutations in their respective genes, *CHD7* or *KMT2D* (100% sensitivity), while giving low scores to samples with mutations in the other gene and to all controls in the Validation Cohort (100% specificity).

The Validation Cohort included one individual with a mutation in *KDM6A*, a second gene in which mutations are associated with Kabuki syndrome.[@bib34] Interestingly, the *KDM6A* mutation received a high score from the *KMT2D*^LOF^ DNAm classification signature model, indicating that it is more similar to *KMT2D*^LOF^ than controls or *CHD7*^LOF^.

Analysis of Sequence Variants in *CHD7* and *KMT2D* Using Gene-Specific DNAm Classification Signatures {#sec3.6}
------------------------------------------------------------------------------------------------------

The predictive models were next applied to cohorts of individuals with *CHD7* and *KMT2D* sequence variants of uncertain significance (VUS) that included missense and splice site mutations ([Figure 4](#fig4){ref-type="fig"}; [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). Phenotypic information for these individuals is summarized in [Tables S3](#mmc2){ref-type="supplementary-material"} and [S4](#mmc2){ref-type="supplementary-material"}. Of 13 individuals with VUS in *CHD7*, 6 clustered with the *CHD7*^LOF^ Discovery Cohort, suggesting that these variants (CHD7-20, 21, 23, 24, 25, and 30) are pathogenic, and 7 clustered with the control samples suggesting that these variants (CHD7-22, 26, 27, 28, 29, 31, and 32) are benign ([Figure 4](#fig4){ref-type="fig"}). The 6 variants predicted to be pathogenic included 2 splice site mutations (one inherited and one de novo) and 4 missense mutations (3 de novo, one inheritance unknown). The inherited splice site mutation was identified in a parent with no overt clinical manifestations of CHARGE syndrome. The parent had a normal ophthalmology exam and did not have a history of hearing loss, but did not undergo imaging of the middle/inner ear. All of the 7 variants predicted to be benign are inherited missense mutations. Of the 10 individuals with VUS in *KMT2D*, 1 clustered with the *KMT2D*^LOF^ Discovery Cohort (KMT2D-12), suggesting that this variant is pathogenic and 8 clustered with the control samples suggesting that these variants (KMT2D-13, 15, 16, 17, 18, 19, 20, and 21) are benign. The KMT2D-14 variant had an intermediate score between the *KMT2D*^LOF^ Discovery Cohort and the control samples. The KMT2D-12 variant predicted to be pathogenic is a de novo missense mutation. The KMT2D-14 variant with the intermediate score is a de novo splice site mutation. The 8 variants predicted to be benign are all inherited missense mutations.

Diagnostic Classification by DNAm Signature versus Clinical Criteria {#sec3.7}
--------------------------------------------------------------------

A comparison of the *CHD7*^LOF^ DNAm classification signature prediction (pathogenic or benign) to the Verloes[@bib17] diagnostic criteria for CHARGE syndrome and that recently proposed by Hale[@bib18] revealed discordant results for four individuals within our *CHD7* variant cohort ([Table 1](#tbl1){ref-type="table"}). Specifically, three individuals who did not meet criteria for a diagnosis of CHARGE using either the Verloes or Hale criteria (CHD7-20, CHD7-21, and CHD7-30) were determined to have pathogenic *CHD7* mutations when classified utilizing the *CHD7*^LOF^ DNAm classification signature. Of note, individual CHD7-21 did not have sufficient clinical information to be classified using the Hale criteria. All three of these mutations were de novo. The fourth individual (CHD7-22) was classified as "partial" CHARGE using the Verloes criteria and met a clinical diagnosis for CHARGE using the Hale criteria but the *CHD7*^LOF^ DNAm classification signature predicted this to be a benign *CHD7* variant. This variant was an inherited synonymous mutation.

Comparison of the *CHD7*^LOF^ DNAm classification signature predictions to independent in silico prediction algorithms, specifically PolyPhen-2^12^, SIFT,[@bib13] Mutation Taster,[@bib14] and ESE finder[@bib15], [@bib16] also revealed discordant results for 5 individuals with missense mutations (CHD7-26, CHD7-27, CHD7-28, CHD7-29, and CHD7-32). Specifically, 5 results were discordant with Mutation Taster, 4 results were discordant with SIFT and 1 result was discordant with PolyPhen-2. However, none of these predictive algorithms were in complete agreement with each other.

Consensus clinical diagnostic criteria for Kabuki syndrome have not been established. Individuals with this condition have characteristic facial features, in addition to a variety of congenital anomalies (intellectual disability, short stature, persistent fingertip pads, and skeletal anomalies), which suggest the diagnosis. Individual KMT2D-12 who clustered with the *KMT2D*^LOF^ Discovery Cohort when the *KMT2D*^LOF^ DNAm classification signature was applied had a clinical diagnosis of Kabuki syndrome (established by O.C.; [Table 2](#tbl2){ref-type="table"}). Individual KMT2D-14 who had an intermediate score between the *KMT2D*^LOF^ Discovery Cohort and the control samples also had a clinical diagnosis of Kabuki syndrome (established by R.M.-L.). Notably, both individuals had typical facial features in addition to other characteristic clinical features.

Genes with Differential DNAm in the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Signatures {#sec3.8}
--------------------------------------------------------------------------------

The majority of CpG sites differentially methylated for *CHD7*^LOF^ and *KMT2D*^LOF^ were specific to each DNAm signature. The *CHD7*^LOF^ CpG sites were located within the bodies or promoter regions (up to 1500 bp upstream of the transcription start site) of 86 known RefSeq genes ([Table S8](#mmc2){ref-type="supplementary-material"}).[@bib35] Several genes demonstrated differential DNAm at multiple probes, including *FOXP2*, HOXA transcript antisense RNA, myeloid-specific 1 (*HOTAIRM1*), homeobox A1 (*HOXA1* \[MIM: [142955](142955){#intref0135}\]), homeobox A6 (*HOXA6* \[MIM: [142951](142951){#intref0140}\]), *HOXA5* and *SLITRK5*. Analysis of differentially methylated regions, using bump hunting,[@bib27] detected consistent patterns of DNAm gain or loss in the vicinity of these genes ([Table S10](#mmc2){ref-type="supplementary-material"}). Enrichment analysis of the probes within the *CHD7*^LOF^ DNAm signature confirmed a statistically significant over-representation in GO Biological Process[@bib31] categories related to growth and embryonic development of the brain, ear, digestive, endocrine, and neural systems, as well as additional functional categories that are highly relevant to the phenotypic features associated with CHARGE syndrome ([Table S12](#mmc2){ref-type="supplementary-material"}).

The *KMT2D*^LOF^ CpG sites were located within the bodies or promoter regions of 105 known genes ([Table S9](#mmc2){ref-type="supplementary-material"}). Among these, multiple CpG sites mapped to *HOTAIRM1*, homeobox A4 (*HOXA4* \[MIM: [142953](142953){#intref0145}\]), *HOXA5*, and *SLITRK5*. These genes were also identified as corresponding to *KMT2D*^LOF^ associated differentially methylated regions detected by bump hunting ([Table S11](#mmc2){ref-type="supplementary-material"}). Enrichment analysis of the probes within the *KMT2D*^LOF^ DNAm signature confirmed a statistically significant over-representation in GO biological processes categories related to skeletal, lung and digestive system development; as well there were functional categories similar to those observed for the *CHD7*^LOF^ signature including pattern specification and embryonic morphogenesis ([Table S13](#mmc2){ref-type="supplementary-material"}).

Due to the presence of both overlapping and clinically distinct features seen in CHARGE and Kabuki syndromes, we examined the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signatures for both shared and distinct CpG targets. There were 14 CpG sites shared by the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signatures: 11 corresponding to *HOXA5* and 3 to *SLITRK5*. The *HOXA5* CpGs demonstrated a gain of DNAm in both the *CHD7*^LOF^ and *KMT2D*^LOF^ signatures. DNAm was validated using sodium bisulfite pyrosequencing for 3 CpG sites in the *HOXA5* promoter (cg01370449, cg04863892, and cg19759481; [Figures 5](#fig5){ref-type="fig"}A--5C). The average gain of DNAm for the three sites is *CHD7*^LOF^ was 18%, 20%, and 20% respectively, compared to 18%, 18%, and 19% for *KMT2D*^LOF^. Furthermore, the analysis of DMRs for *CHD7*^LOF^ and *KMT2D*^LOF^ using bump hunting also confirmed gain of DNAm at overlapping DMRs in the vicinity of *HOXA5* ([Figure S4](#mmc1){ref-type="supplementary-material"}A). The shared CpG sites near *SLITRK5* demonstrated DNAm changes in opposite directions in the two signatures, with a loss of DNAm in *CHD7*^LOF^ but gain of DNAm in *KMT2D*^LOF^. For *SLITRK5*, 3 CpG sites (cg16787483, cg24626752, and cg09823859; [Figures 5](#fig5){ref-type="fig"}D--5F) were validated using pyrosequencing. An average loss of DNAm of 20%, 14%, and 12% in the *CHD7*^LOF^ samples was confirmed, whereas an average gain of DNAm of 21%, 24%, and 24% was confirmed in *KMT2D*^LOF^ samples. This finding was confirmed by bumphunting in the overlapping DMRs ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

DNAm was also validated for CpG sites in genes specific to each DNAm signature. For the *CHD7*^LOF^ DNAm signature two CpG sites in *FOXP2* (cg18546840 and cg18871253) were selected because of the critical role of FOXP2 in brain and craniofacial development.[@bib36], [@bib37] Both of these CpG sites exhibit an average loss of DNAm of 15% ([Figures 5](#fig5){ref-type="fig"}G and 5H). For the *KMT2D*^LOF^ DNAm signature a CpG site in *MYO1F* (cg15254671) with an average 33% loss of DNAm ([Figure 5](#fig5){ref-type="fig"}I) was validated. This CpG site, along with four others in the same CpG island (spanning exon 23 to 24), carry chromatin marks classified as a promoter or enhancer in different cell types.[@bib38], [@bib39]

Discussion {#sec4}
==========

We have identified two unique DNAm signatures associated with loss of function mutations in *CHD7* (*CHD7*^LOF^) and *KMT2D (KMT2D*^LOF^*)*, further enhancing our understanding of the critical role of epigenetic dysregulation in neurodevelopmental disorders. These two gene-specific signatures demonstrate 100% specificity and 100% sensitivity, enabling differentiation between pathogenic and benign mutations in *CHD7* and *KMT2D*, respectively. That is, these DNAm signatures can function as tools to classify variants of unknown significance (VUS) in these genes. Interestingly, comparisons of the differentially methylated sites within the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signatures provide evidence that CHD7 and KMT2D regulate common biological pathways likely reflecting the clinical overlap between CHARGE and Kabuki syndromes.

Functional Roles of CHD7 and KMT2D {#sec4.1}
----------------------------------

Mutations in *CHD7* were initially identified as the etiology of CHARGE syndrome in 2004.[@bib1] Since that time, much has been learned regarding the biological function of this gene. CHD7, an ATP-dependent chromodomain helicase chromatin remodeling protein is involved in the formation of several large protein complexes that regulate the movement of nucleosomes along DNA, and as such affects the activity of numerous signaling pathways during embryonic development.[@bib40] These CHD7-containing protein complexes bind to DNA at specific sites, the majority of which overlap with regulatory elements such as gene promoters or enhancers.[@bib41], [@bib42] The epigenetic effects of CHD7 on chromatin and gene regulation appear to vary both temporally and spatially, depending largely upon the function of the protein complex with which it interacts (for review see [@bib43]). *CHD7* is expressed in embryonic stem cells; its expression becomes restricted to specific tissues, including the brain, eye, heart, and ear, during differentiation.[@bib44] Gene-expression studies in mouse embryos carrying a homozygous deletion of *Chd7* demonstrate significant expression differences in many genes important for brain development.[@bib45]

Mutations in *KMT2D* were initially identified as the major cause of Kabuki syndrome in 2010.[@bib2] KMT2D, a lysine methyltransferase, adds a tri-methyl mark to histone 3 lysine 4 (H3K4), which promotes gene expression by facilitating open chromatin conformation.[@bib46] *KMT2D* belongs to the family of mixed-lineage leukemia (MLL) genes, which are involved in controlling other genes essential for embryogenesis, including the *HOX* genes.[@bib47], [@bib48] In a mouse model of Kabuki syndrome, heterozygous disruption of *Kmt2d* is associated with a genome-wide reduction of H3K4 tri-methylation.[@bib49] Histone methylation patterns in cardiac tissue from embryos with homozygous deletions of *Kmt2d* show a global decrease in H3K4 mono- and di-methylation, when compared to controls, suggesting that KMT2D functions at both enhancers and gene promoters to regulate gene expression.[@bib47]

Utility of *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Signatures {#sec4.2}
-------------------------------------------------------

Diagnosis of CHARGE and Kabuki syndromes in the clinical setting can be challenging. CHARGE syndrome in particular has been shown to have extensive intra- and interfamilial clinical variability.[@bib50], [@bib51] Since the first description of CHARGE syndrome in 1981, diagnostic criteria for this condition have undergone several iterations, reflecting a broadening of the phenotype.[@bib17], [@bib18], [@bib52], [@bib53] The challenges in establishing a clinical diagnosis of CHARGE syndrome using existing diagnostic criteria ([Table 1](#tbl1){ref-type="table"}) are highlighted by data for four individuals in the current study, that demonstrate incongruities between the criteria-based clinical classifications of CHARGE syndrome and our *CHD7*^LOF^ DNAm classification signature predictions. Specifically, three individuals who did not meet clinical criteria for a diagnosis of CHARGE syndrome were identified to have the DNAm signature (predicting pathogenicity) and one individual who did meet clinical criteria for a diagnosis of CHARGE syndrome did not have the DNAm signature (predicting a benign variant). Existing in silico prediction tools often provide different and contradictory results as seen for several of the individuals in our *CHD7* variant cohort.[@bib54] We propose that our *CHD7*^LOF^ DNAm classification signature could be used as a functional molecular test to aid in the interpretation of the pathogenicity of *CHD7* sequence variants, providing a valuable tool to facilitate in the diagnosis of CHARGE syndrome.

Similarly, the *KMT2D*^LOF^ DNAm classification signature could be used to assess the pathogenicity of *KMT2D* sequence variants ([Table 2](#tbl2){ref-type="table"}). For example, in the case of the two individuals with *KMT2D* VUS, the DNAm classification signature provided functional molecular validation for a suspected clinical diagnosis when sequence analysis did not provide a definitive answer.

For individuals reported to have putative pathogenic variants in *CHD7*, 17% do not fulfill diagnostic criteria for CHARGE syndrome, further demonstrating the phenotypic variability and the imperfect alignment between clinical classification and molecular test data.[@bib55], [@bib56] Further, although pathogenic mutations in *CHD7* are identified in 90% of individuals fulfilling Blake's criteria, only 65%--70% of individuals with typical or suspected CHARGE syndrome are identified to have a pathogenic *CHD7* mutation.[@bib55], [@bib57] Similarly, only ∼70% of individuals with a clinical diagnosis of Kabuki syndrome are identified to have pathogenic mutations in *KMT2D* or *KDM6A*[@bib58]. It is not clear whether the missing 30% of mutations occur in promoters or enhancers not identified by current sequencing techniques or if there might be locus heterogeneity. The *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signatures could provide a means of enhancing the molecular diagnostic rates for these syndromes, because they could detect loss of function mutations that might not be detected by current sequence-based testing. In future, further validation of the clinical utility of these signatures could be derived from RNA sequence-based functional assays.

The utility of DNAm signatures for the epigenes *CHD7* and *KMT2D* constitute a generalization of our previous work with epigenes, in which we demonstrated the utility of a DNAm signature in classifying VUS in *NSD1* associated with Sotos syndrome.[@bib8] The *NSD1*-specific DNAm signature also enabled molecular distinction between Sotos syndrome and the clinically overlapping overgrowth condition Weaver syndrome \[MIM: [277590](277590){#intref0150}\] resulting from mutations in enhancer of zeste, *Drosophila*, homolog 2 (*EZH2* \[MIM: [601573](601573){#intref0155}\]), another epigene encoding a histone methyltransferase.[@bib59], [@bib60]

Overlapping Molecular Mechanisms for CHARGE and Kabuki Syndromes {#sec4.3}
----------------------------------------------------------------

Clinical overlap between CHARGE and Kabuki syndromes was initially reported by Ming et al. (2003) over 10 years ago.[@bib3] Since then, several reports have demonstrated the difficulty in distinguishing between these two conditions, especially in infancy when the typical facial gestalt of Kabuki syndrome might not yet be apparent.[@bib4], [@bib61], [@bib62] Overlapping clinical features include postnatal growth retardation, cleft lip/palate, hearing loss, congenital heart defects, urogenital malformations, developmental delay, and intellectual disability. As well, ocular coloboma, which is a major diagnostic criterion for CHARGE syndrome, has occasionally been reported in individuals with Kabuki syndrome.[@bib4], [@bib61], [@bib62] The genes associated with CHARGE (*CHD7*) and Kabuki (*KMT2D* and *KDM6A*) syndromes all play a role in chromatin remodeling. Evidence supporting a functional connection between CHD7 and KMT2D comes from studies showing that both these protein interact with members of the WAR complex (WDR5, RBBP5, and ASH2L).[@bib6], [@bib7], [@bib63] On the basis of these findings, it was suggested that CHD7 and KMT2D regulate a common subset of genes.[@bib7] Our finding that the unique *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm signatures have common CpG targets, specifically within *HOXA5* and *SLITRK5*, provides additional evidence for molecular mechanistic connections between CHARGE and Kabuki syndromes and also provides important functional data to explain the pathophysiologic basis of the overlapping features in these two conditions.

Our previous work on *NSD1* demonstrated the relevance of the DNAm targets in blood to our understanding of the pathophysiology of the disease. In the case of *NSD1* loss of function mutations, DNAm gene targets were enriched for neural and cellular development pathways, reflecting the cardinal features of Sotos syndrome (overgrowth and developmental delay).[@bib8] Our finding that the *CHD7* and *KMT2D* DNAm targets appear to relate to genes involved in the embryonic development of cell types and tissues demonstrating malformations in CHARGE and Kabuki syndromes further supports the functional significance of these DNAm signatures and provides valuable data relevant to the pathophysiology of these conditions.

Both CHD7 and KMT2D have been previously linked to expression of various homeobox-containing genes. The homeobox (*HOX*) genes encode highly conserved transcription factors that are expressed in a spatially and temporally regulated manner during development.[@bib64] *HOX* expression during development is tightly regulated in part by chromatin structure and epigenetic modifications, including DNAm.[@bib65] In the mouse, the developing neural tube of *Chd7*^−/−^ embryos also showed altered expression of other homeobox genes, such as orthodenticle homeobox 2 (*Otx2*) and gastrulation brain homeobox 2 *(Gbx2)*.[@bib66] Chromatin immunoprecipitation assays have shown that CHD7 binds to other chromatin-associated proteins at genomic sites within the *HOXA1*, *HOXA5*, and *HOXA6*.[@bib41] In fibroblast cells from individuals with loss of function *KMT2D* mutations, targeted expression analysis of homeobox C6 *(HOXC6* \[MIM: [142972](142972){#intref0160}\]) showed a decreased transcript level compared to controls.[@bib67] KMT2D has also been shown to bind to DNA in the *HoxA* cluster in mouse embryonic-stem-cell-derived cardiomyocytes.[@bib47]

The finding that *HOXA5* is regulated by both CHD7 and KMT2D provides us with further clues to the pathophysiology of CHARGE and Kabuki syndromes. In both the *CHD7*^LOF^and *KMT2D*^LOF^ DNAm signatures, a gain in DNAm was observed at the *HOXA5* promoter. Functional studies in a wide range of vertebrate species have established the conserved roles of *HOX* genes as transcription factors that regulate axial patterning of the developing embryo.[@bib68] A study of the mouse promoter *HoxA5* showed that it is unmethylated in specific embryonic tissues, including liver, intestine, and spleen.[@bib69] In those same tissues postnatally, the *HoxA5* promoter becomes completely (spleen), or partially (intestine) unmethylated, or remains unmethylated (liver). Therefore, DNAm appears to be a crucial element in the developmental regulation of *Hox* activity postnatally. Our findings of a 20% increase in DNAm is likely to be functionally relevant given data from a mouse model wherein a high-fat diet is associated with a 25% increase in DNA methylation of the *Hoxa5*promoter in adipose tissue resulting in a significant reduction in mRNA and protein expression of this gene.[@bib70]

Some of the clinical features shared by CHARGE and Kabuki syndromes could be mediated by reduced expression of *HOXA5*. Based on functional studies of HOXA5 in mice, we propose that these could include growth deficiency, skeletal and limb anomalies, renal dysgenesis, and neural development.[@bib71], [@bib72], [@bib73], [@bib74], [@bib75] In one mouse model with heterozygote *Hoxa5* truncating mutations, the mutant mice were phenotypically indistinguishable from their wild-type littermates but on further evaluation of skeletal morphology, an increased rate of rib anomalies/vertebral defect were identified.[@bib76] Of interest, individuals with CHARGE and Kabuki syndromes demonstrate vertebral anomalies and individuals with CHARGE syndrome can have missing ribs.[@bib77] Additional studies focused on the brain and behavior of these mice could demonstrate important changes in brain function and/or behavior given a recent report characterizing the expression profile and the neuroanatomical localization of HOXA5 in the fetal, postnatal, and adult brain.[@bib75] They identified *Hoxa5* transcripts in the medulla oblongata and the pons from fetal to adult stages, and in the thalamus and the cortex from postnatal stages through adulthood. They also demonstrated that *Hoxa5* is transcribed in the adult cerebellum and that the HOXA5 protein is present in all the *Hoxa5*-expressing hindbrain nuclei in adulthood. This suggests that HOXA5 in these nuclei might be required for processes beyond the early developmental patterning and neuronal migration phases, including axonal growth and synapse formation during circuit establishment, refinement of neural circuits during early postnatal life in response to environmental cues, or adult synaptic plasticity.[@bib75] Interestingly, in each of the DNAm signatures there are multiple *HOXA* genes that have differential DNAm, including *HOTAIRM*, *HOXA1*, and *HOXA6* in *CHD7*^LOF^ and *HOXA4* in *KMT2D*^LOF^.

*HOTAIRM* is a long non-coding RNA (lncRNA), which has been found to interact with different chromatin-modifying complexes.[@bib78] Recent work by Wang and Dostie (2016) found that *HOTAIRM1* contributes to three-dimensional changes in chromatin organization required for the temporal collinear activation of *HOXA* genes.[@bib79] Their findings also demonstrate that lncRNAs derived from the *HOTAIRM1* gene can activate and/or repress *HOXA* gene expression in different cell types. Our finding that *CHD7*^LOF^ is associated with differential DNAm at *HOTAIRM* suggests multiple layers of epigenetic dysregulation impacting cell-type-specific *HOXA* gene expression in CHARGE syndrome. *HOTAIRM1* is also known to modulate β-integrin signaling, which has been shown to be critical for the expansion of neural stem cells in the development of the cerebral cortex of model organisms.[@bib80], [@bib81] These data suggest specific pathophysiologic mechanisms that could account for neurodevelopmental anomalies in CHARGE syndrome.

A second gene, *SLITRK5*, also had shared differentially methylated CpG sites in the gene body and surrounding shores in each of the DNAm signatures with a loss of DNAm in *CHD7*^LOF^ and a gain of DNAm in *KMT2D*^LOF^. The *SLITRK* family encodes transmembrane proteins which function at synapses[@bib82], [@bib83]. *SLITRK5* has been shown to function in synaptic adhesion and in tropomyosin receptor kinase B (TRKB) signaling upon brain-derived neurotrophic factor (BDNF) stimulation.[@bib84] In *Chd7*^−/−^ mouse whole embryos, expression of *SLITRK5* is decreased.[@bib45] Mice with homozygous deletion of *Slitrk5* develop an over-grooming phenotype and deficiencies in corticostriatal transmission as well as a reduction in glutamate receptor subunits.[@bib85] We expect that dysregulation of *SLITRK5*, either gain or loss, could impact neuronal development due to its role in many tightly regulated processes at the synapse.

Epigenetic Targets Specific to CHARGE and Kabuki Syndromes {#sec4.4}
----------------------------------------------------------

One of the genes specific to the *CHD7*^LOF^ DNAm signature is *FOXP2*. In mice, FOXP2 has been shown to be expressed in the motor related circuitry in the brain, which controls craniofacial development including muscles of the face and striatal brain development.[@bib36], [@bib37] In mouse embryonic stem cells and neural progenitors, chromatin immunoprecipitation assays show that CHD7 binds to the *Foxp2* promoter.[@bib41] As mutations in *FOXP2* have been identified in individuals with speech and language deficits,[@bib86] it is possible that altered *FOXP2* expression might contribute to the speech and language difficulties in individuals with CHARGE syndrome.

Specific to the *KMT2D*^LOF^ DNAm signature are CpG sites within the gene body of *MYO1F*. These sites are located in a CpG island carrying chromatin marks which classify the region as regulatory, specifically as a promoter or enhancer in different cell types.[@bib38], [@bib39] This unconventional myosin is expressed in the inner ear and heterozygous missense mutations in this gene have been identified in individuals with hereditary hearing loss.[@bib87]

Overlapping Epigenetic Targets for KMT2D and KDM6A in Kabuki Syndrome {#sec4.5}
---------------------------------------------------------------------

Our observation that the single sample from with a *KDM6A* pathogenic mutation in the Validation cohort clustered with the pathogenic *KMT2D* samples suggests that these two genes regulate overlapping sets of genes. This is in keeping with evidence from earlier studies that showed these two proteins share *HOX* targets.[@bib88] KDM6A, a histone demethylase, has been shown to interact with KMT2D as part of a multi-protein complex.[@bib89] More recently, the majority of KDM6A target genes have been shown to be co-regulated by KMT2D.[@bib90] Knockdown of the zebrafish orthologs of KMT2D and KDM6A confirmed the role of these proteins in craniofacial, heart, and brain development, providing direct evidence of the overlapping, functional roles of these genes in the development of tissues and organs affected in Kabuki syndrome.[@bib91] DNAm analysis of additional samples with *KDM6A* pathogenic mutations will be required to assess for potentially overlapping yet distinct DNAm signatures. Such a study would also allow for a comparison of the target genes regulated by KMT2D and KDM6A furthering our understanding of the overlapping and distinct functions of these two genes in the etiology of Kabuki syndrome.

Potential for Therapeutic Interventions Based on Epigenetic Targets {#sec4.6}
-------------------------------------------------------------------

As our knowledge of epigenetic regulation in neurodevelopmental disorders increases, so does the opportunity for therapeutic interventions. The potential positive impact of such interventions is heightened by compelling evidence for the potential to reverse *postnatally* neurological phenotypes in mouse models of Rett syndrome (*RTT* \[MIM: [312750](312750){#intref0165}\]) caused by mutations in the epigene methyl-CpG binding protein 2 (*MECP2* \[MIM: [300005](300005){#intref0170}\]).[@bib92] Recently, Bjornsson et al. (2014) showed that memory deficits in a mouse model of Kabuki syndrome (*Kmt2d* ^+/\ βGeo^) can be prevented or even reversed through systemic delivery of a histone deacetylase (HDAC) inhibitor, which promotes open chromatin states.[@bib49] Their findings provide support for the hypothesis that neurodevelopmental deficits in Kabuki syndrome are maintained by an impairment of adult neurogenesis because of an imbalance between open and closed chromatin states for critical target genes. We propose that *HOXA5* (regulated by both CHD7 and KMT2D), which has recently been found to be transcribed in the adult brain might be one of these critical target genes.[@bib93] A more general potential therapeutic role for HDAC inhibitors in neurodevelopmental syndromes caused by certain epigenes is supported by the fact that these inhibitors have also been shown to reverse the long term memory deficit in mouse models of Rubinstein-Taybi syndrome (*RSTS1* \[MIM: [180849](180849){#intref0175}\]) caused by haploinsufficient mutations in another epigene, histone acetyltransferase *CREBBP* (cAMP-responsive element binding protein binding protein \[MIM: 600140\]).[@bib93]

Conclusion {#sec4.7}
----------

In this article, we present DNAm signatures for *CHD7* and *KMT2D* in human blood cells which hold promise for translational clinical use. These signatures, which have a high degree of sensitivity and specificity, identify specific target genes in human blood cells regulated by CHD7 and KMT2D. Our findings provide evidence that CHARGE and Kabuki syndromes result from dysregulatrion of key genes involved embryonal development that are expressed in a tissue-specific manner. Future studies in developmental model systems such as human induced pluripotent stem cells will help to enhance our understanding of epigenetic regulation in diverse cell-types, including neuronal cells. The field of epigenomics offers a host of opportunities to positively impact precision medicine including a robust means of classifying pathogenicity of VUS and understanding disease pathophysiology in the context of genome-wide targets of epigenes. The identification of a multitude of gene-specific targets across the genome provides tangible opportunities to explore novel therapeutics to reverse neurodevelopmental deficits caused by epigenetic dysregulation.
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![Hierarchical Clustering of the Discovery Cohorts Using the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Signatures\
The heatmap shows the unsupervised hierarchical clustering of (A) 19 *CHD7*^LOF^ individuals and 29 matching controls samples, using only 163 differentially methylated CpG sites specific to *CHD7*^LOF^. The color gradient of the heatmap indicates the methylation level, from low (blue) to high (yellow). DNAm profiles fall into two separate clusters corresponding to *CHD7*^LOF^ mutations (red) and controls (green). Euclidean distance metric is used in the clustering.\
(B) 11 *KMT2D*^LOF^ individuals and 11 matching controls samples, using only 221 differentially methylated CpG sites specific to *KMT2D*^LOF^. DNAm profiles fall into two separate clusters corresponding to *KMT2D*^LOF^ mutations (blue) and controls (green).](gr1){#fig1}

![Specificity of the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Classification Signatures\
The plot shows the predictions for all samples from the original Discovery Cohorts, as well as for 162 normal blood samples extracted from the GEO repository. The x axis shows the predictive scores generated from the *CHD7*^LOF^*-*specific predictive model derived using the *CHD7*^LOF^ individuals and matching controls. The y axis shows the predictive score of the *KMT2D*^LOF^-specific predictive model derived using the *KMT2D*^LOF^ individuals and matching controls. Importantly, using the *KMT2D*^LOF^-specific model all 19 *CHD7*^LOF^ (red C) received low scores, along with all *CHD7*^LOF^ matching controls (red circles) and all GEO samples (green crosses). Similarly, using the *CHD7*^LOF^-specific model all 11 *KMT2D*^LOF^ (blue K) received low scores, along with all *KMT2D*^LOF^ matching controls (blue diamonds) and all GEO samples (green crosses).](gr2){#fig2}

![Validation of *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Classification Signatures on a Blinded Cohort\
We derived the scores for each sample using the two predictive models built for the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm classification signatures (x axis and y axis, respectively; see [Figure 2](#fig2){ref-type="fig"}), for a validation set of DNAm samples. This set included both pathogenic mutations and VUS in *CHD7* (red squares), *KMT2D* (blue triangles) and *KDM6A* (turquoise diamond). The mutation and their pathogenicity were initially blinded and were revealed only after the prediction scores were determined. Importantly, all *CHD7* mutations received low scores by the *KMT2D*-specific predictive model, and vice versa. Pathogenic mutations in *CHD7* (filled red squares) received high scores from the *CHD7*^LOF^ model, and pathogenic mutations in *KMT2D* (filled blue triangles) received very high scores from the *KMT2D*^LOF^ model. Interestingly, a pathogenic mutation in the Kabuki-associated gene *KDM6A* also received a very high score from the *KMT2D*^LOF^ model, indicating a potential methylation-signature overlap between these two genes.](gr3){#fig3}

![Sequence Variants in *CHD7* and *KMT2D* Sorted Using the *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm Classification Signatures\
We derived the scores for each individual using the two models generated for *CHD7*^LOF^ and *KMT2D*^LOF^ DNAm classification signatures (x axis and y axis, respectively; see [Figure 2](#fig2){ref-type="fig"}), for a set of 13 mutation variants in *CHD7* (red crossed circles) and 10 mutation variants in *KMT2D* (blue crossed squares). The details of the sample classification are shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}.](gr4){#fig4}

![Targeted Sodium Bisulfite Pyrosequencing Validation of DNAm Alterations in *CHD7* and *KMT2D* Discovery Cohorts\
(A--C) DNAm was assessed for three CpG sites in the promoter of *HOXA5* (cg01370449, cg04863892, and cg19759481). The gain of DNAm for the three sites in *CHD7*^LOF^: 18%, 20%, and 20%. For *KMT2D*^LOF^ there was also a gain of DNAm: 18%, 18%, and 19%, respectively. Both the *CHD7*^LOF^ and *KMT2D*^LOF^group are statistically different from the controls for all three probes, but not from each other.\
(D--F) DNAm was assessed for three CpG sites in the gene body of *SLITRK5* (cg16787483, cg24626752, and cg09823859). A loss of DNAm of 20%, 14%, and 12% in the *CHD7*^LOF^ samples and a gain of DNAm of 21%, 24%, and 24% in *KMT2D*^LOF^ samples are shown. Both the *CHD7*^LOF^ and *KMT2D*^LOF^group are statistically different from the controls for all three probes, and from each other.\
(G and H) DNAm was analyzed for *FOXP2* (cg18546840 and cg18871253) in *CHD7*^LOF^, which had a 15% loss of DNAm compared to controls.\
(I) DNAm was analyzed for *MYO1F* (cg15254671) in *KMT2D*^LOF^, which had a loss of DNAm of 33% compared to controls. Testing for a statistical difference between all groups was performed using a Kruskal-Wallis test; ^∗^p \< 0.0001.](gr5){#fig5}

###### 

Classification of *CHD7* Sequence Variants Utilizing DNAm Signatures, Clinical Criteria and In Silico Prediction Algorithms

  **[Sample ID]{.ul}**   **[Mutation]{.ul}**    **[Protein Change]{.ul}**             **[Inheritance]{.ul}**   **[Signature (positive/negative)]{.ul}**   **Verloes criteria (2005)**   **Hale proposed criteria (2015)**   **[SIFT (score)]{.ul}**   **[Mutation Taster (p value)]{.ul}**   **[PolyPhen-2 prediction effect (score)]{.ul}**
  ---------------------- ---------------------- ------------------------------------- ------------------------ ------------------------------------------ ----------------------------- ----------------------------------- ------------------------- -------------------------------------- -------------------------------------------------
  CHD7-20                c.6322G\>T             p.Gly2108Trp                          de novo                  positive                                   N                             N^∗^                                Deleterious (0)           Disease Causing (1)                    Probably Damaging (1)
  CHD7-21                c.3746G\>A             p.Arg1249Gln                          de novo                  positive                                   N                             I                                   Deleterious (0)           Disease Causing (1)                    Probably Damaging (1)
  CHD7-22                c2751G\>A              p\. Thr917 =                          inherited                negative                                   P                             Y                                   ND                        ND                                     ND
  CHD7-23                c.-15G\>A              ND[a](#tblfn1){ref-type="table-fn"}   inherited                positive                                   A                             Y                                   ND                        ND                                     ND
  CHD7-24                c.4225G\>A             p.Val1409Met                          not maternal             positive                                   P                             Y                                   Deleterious (0)           Disease Causing (1)                    Probably Damaging (0.997)
  CHD7-25                c.5436C\>G             p.Asp1812Glu                          de novo                  positive                                   I                             I                                   Deleterious (0)           Disease Causing (1)                    Probably Damaging (1)
  CHD7-26                c.5633A\>G             p.Asp1878Gly                          inherited                negative                                   I                             I                                   Deleterious (0.01)        Disease Causing (1)                    Benign (0.394)
  CHD7-27                c.5848G\>A             p.Ala1950Thr                          inherited                negative                                   I                             I                                   Deleterious (0)           Disease Causing (1)                    Benign (0.057)
  CHD7-28                c.6304G\>T             p.Val2102Phe                          inherited                negative                                   I                             I                                   Deleterious (0.05)        Disease Causing (0.969)                Benign (0.389)
  CHD7-29                c.3566G\>A             p.Arg1189His                          inherited                negative                                   I                             I                                   Deleterious (0)           Disease Causing (1)                    Probably Damaging (1)
  CHD7-30                c2238+1del             ND[b](#tblfn2){ref-type="table-fn"}   de novo                  positive                                   N                             N^∗^                                ND                        ND                                     ND
  CHD7-31                c.2049_2050insAAAGCA   p.Ala685_Lys686dup                    inherited                negative                                   I                             I                                   ND                        ND                                     ND
  CHD7-32                c.6377A\>T             p.Asp2126Val                          inherited                negative                                   N                             N                                   Tolerated (0.13)          Disease Causing (1)                    Benign (0.014)

CHARGE Criteria Legend: N, does not meet criteria; p, partial CHARGE; A, atypical CHARGE; Y, meets criteria;

I, insufficient information to classify; N^∗^, meets criteria if variant considered pathogenic; ND, not determined.

ESEfinder Splicing Prediction for CHD7-23 identifies loss of a SF2/ASF site.

ESEfinder Splicing Prediction for CHD7-30 identifies a gain of a SC35 site.

###### 

Classification of *KMT2D* Sequence Variants Utilizing DNAm Signatures and In Silico Prediction Algorithms

  **[Sample ID]{.ul}**   **[Mutation]{.ul}**      **[Protein change]{.ul}**             **[Inheritance]{.ul}**   **[Signature (positive/negative)]{.ul}**   **[SIFT (score)]{.ul}**   **[Mutation Taster(p value)]{.ul}**   **[PolyPhen-2 prediction effect (score)]{.ul}**
  ---------------------- ------------------------ ------------------------------------- ------------------------ ------------------------------------------ ------------------------- ------------------------------------- -------------------------------------------------
  KMT2D-12               c.15143G\>A              p.Arg5048His                          de novo                  positive                                   Deleterious (0)           Disease Causing (1)                   Probably Damaging (1)
  KMT2D-13               c.12028T\>C              p.Ser4010Pro                          inherited                negative                                   Tolerated (0.28)          Polymorphism (1)                      Benign (0.001)
  KMT2D-14               c.16522-5_16522-4delTT   ND[a](#tblfn3){ref-type="table-fn"}   de novo                  positive                                   ND                        ND                                    ND
  KMT2D-15               c.15910A\>G              p.Ile5304Val                          inherited                negative                                   Tolerated (0.06)          Disease Causing (1)                   Probably Damaging (0.997)
  KMT2D-16               c.15659G\>A              p.Arg5220His                          inherited                negative                                   Deleterious (0.01)        Disease Causing (1)                   Probably Damaging (1)
  KMT2D-17               c.10256A\>G              p.Asp3419Gly                          inherited                negative                                   Tolerated (0.2)           Disease Causing (1)                   Probably Damaging (1)
  KMT2D-18               c.8974G\>A               p.Glu2992Lys                          inherited                negative                                   Tolerated (0.08)          Disease Causing (1)                   Probably Damaging (0.0996)
  KMT2D-19               c.8831A\>G               p.Asn2944Ser                          inherited                negative                                   Tolerated (0.27)          Polymorphism (1)                      Benign (0.013)
  KMT2D-20               c.832G\>A                p.Ala278Thr                           inherited                negative                                   Tolerated (0.53)          Polymorphism (0.98)                   Benign (0)
  KMT2D-21               c.682C\>G                p.Arg228Gly                           inherited                negative                                   Deleterious (0.02)        Polymorphism (0.883)                  Benign (0.36)

ND = not determined

ESEfinder Splicing Prediction for KMT2D-14 identifies loss of a SF2/ASF site.

[^1]: These authors contributed equally to this work
